Autoimmune hemolytic anemia long-term study
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at people with autoimmune hemolytic anemia (AIHA) over time. It aims to understand the disease better and find ways to improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with autoimmune hemolytic anemia (AIHA).
- Your hemoglobin level is below 100 g/L.
- You were treated at the Institute of Hematology and Blood Diseases Hospital in China on or after January 1, 2001.
- You must be available for long-term follow-up.
- You do not have severe health problems or alcohol/drug dependence that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called Inaticabtagene Autoleucel (a personalized treatment made from your own immune cells) for people with autoimmune hemolytic anemia that has not improved after three or more prior treatments. The goal is to see if this therapy can stop the immune system from destroying red blood cells and help increase your hemoglobin levels.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests a new treatment called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not improved with other treatments. It aims to see if this therapy can help control the disease and improve blood counts.
This trial tests whether adding sirolimus (a medication that calms the immune system) to standard steroid treatment is better than steroids alone for people newly diagnosed with mild autoimmune hemolytic anemia (AIHA). It may help control the disease with fewer side effects.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
Hear when a new AIHA - Warm Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.